Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...
As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...
The latest award from the Administration for Strategic Preparedness and Response of $72 million includes $37.9 million for CSL, $23.4 million for Sanofi, and $10.5 million for GSK. Read Next: ...
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...
Now it’s trading hands again, through a deal announced Friday. Sanofi is selling global rights to Enjaymo to the Italy-based drugmaker Recordati, in exchange for an upfront payment of $825 million.
As such, its use locally so far has been limited. Sanofi, however, recently announced that they will discontinue production of Dengvaxia due to a lack of demand globally. Another vaccine that was ...
Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...
Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of the equity check for its bid for Sanofi’s consumer-health division ...
Regeneron REGN1.05%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN-0.46%decrease; red down pointing triangle have won U.S. Food and Drug Administration expanded approval of ...
MANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of ...